BioNTech SE

NASDAQ:BNTX

Biotechnology

Healthcare
$83.26 -1.52%

-$1.41 today

Market cap
$20.64B
Beta
1.32
P/E (TTM)
-16.2
EPS (TTM)
-$4.93
52W Low $79.52High $124.00

Volume 1.24M

Average 1.11M

BNTX Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

BioNTech SENASDAQ: BNTX

Deferred Revenue · Q2 FY2026 · quarter ended Jun 2026

Deferred revenue falls 21.5% from a year ago

Deferred revenue stood at €742.19M at the end of Q2 FY2026, down 21.5% from a year earlier and down 2.3% from the prior quarter. Over 3 fiscal years it compounded at +113.9% a year.

Context

  • Deferred revenue amounted to 3.6% of total assets at the end of Q2 FY2026, down 0.7 pp from a year earlier.
  • Deferred revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether deferred revenue keeps falling in the next quarterly balance sheet after a -21.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
€742.19M-2.3% QoQ
Last fiscal yearDec 2025
€754.58M+155.9% YoY
Year agoJun 2025
€945.4M-21.5% since
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-21.5%——
1 year+155.9%——
3-year CAGR+113.9%——
5-year CAGR——
10-year CAGR——

Deferred Revenue history

EUR · from the balance sheet

Latest · FY2025
754.58M EUR
Year-over-year change
+155.9%
4-year CAGR
+41.9%

Deferred Revenue vs competitors

How BNTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so deferred revenue is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -21.5% is the 4th highest of 5, against a peer median of +124.5%.
  • Deferred revenue amounts to 3.6% of total assets for BNTX, versus a peer median of 0.1%.
BNTX Competitors
Deferred Revenue for BNTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BNTXBioNTech SEJun 2026€742.19M EUR-21.5%+113.9%3.6%
MGNXMacroGenics, Inc.Mar 2026$67.99M USD+335.3%+3.0%31.2%
TGTXTG Therapeutics, Inc.Sep 2026$26.1M USD-1.1%—1.6%
GMABGenmab A/SJun 2026$21M USD+250.1%—0.2%
IMTXImmatics N.V.Mar 2026€13.24M EUR-47.7%-37.6%2.4%
CGENCompugen Ltd.Mar 2026$11.6M USD——8.0%
IMCRImmunocore Holdings plcMar 2026$572K USD—-57.8%0.1%
INCYIncyte CorporationJun 2026$0 USD——0.0%
IBRXImmunityBio, Inc.Sep 2026$0 USD——0.0%
IOVAIovance Biotherapeutics, Inc.Sep 2026$0 USD——0.0%
XNCRXencor, Inc.Jun 2026$0 USD——0.0%
Peer median (excluding BNTX) —+124.5%-37.6%0.1%

Competitors are the stored peer set for BNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents1.69B13.88B11.66B9.76B7.67B
Short-term Investments381.6M189.4M4.89B7.02B7.16B
Net Receivables12.38B7.15B2.34B1.52B984.48M
Inventory502.5M439.6M357.7M283.3M110.65M
Other Current Assets113.4M271.9M280.9M212.7M210.71M
Total Current Assets15.07B21.92B19.53B18.8B16.14B
Property, Plant & Equipment (Net)520.4M821.1M971.6M1.18B1.29B
Goodwill57.8M61.2M362.5M380.6M367.74M
Intangible Assets144.6M158.5M804.1M790.4M1.61B
Long-term Investments21.3M80.2M1.18B1.25B2.49B
Tax Assets0229.6M81.3M81.7M13.49M
Other Non-current Assets14.4M6.5M83.4M36.1M76.97M
Total Non-current Assets758.5M1.36B3.48B3.73B5.84B
Total Assets15.83B23.28B23.01B22.53B21.98B
Account Payables160M204.1M354M426.7M534.67M
Short-term Debt129.9M36M28.1M39.5M52.18M
Tax Payables1.57B595.9M525.5M4.5M0
Deferred Revenue186.1M77.1M353.3M294.9M754.58M
Other Current Liabilities1.44B2.04B809.6M1.76B734.39M
Total Current Liabilities3.48B2.95B2.07B2.52B2.14B
Long-term Debt171.6M176.2M191M214.7M29.89M
Deferred Tax Liabilities66.7M6.2M39.7M42.4M84.26M
Deferred Revenue (Non-current)9M48.4M398.5M183M87.96M
Other Non-current Liabilities208.2M42.1M60.7M155.3M234.5M
Total Non-current Liabilities455.5M272.9M689.9M595.4M621.84M
Total Liabilities3.94B3.22B2.76B3.12B2.76B
Common Stock246.3M248.6M248.6M248.6M258.89M
Retained Earnings9.88B18.83B19.76B19.1B17.95B
Accumulated OCI93.9M(848.9M)(984.6M)(1.33B)(1.46B)
Other Stockholders Equity00000
Minority Interest00000
Total Equity11.89B20.06B20.25B19.41B19.22B
Total Debt301.5M212.2M219.1M254.2M267.29M
Net Debt(1.39B)(13.66B)(11.44B)(9.51B)(7.4B)

BioNTech SE

NASDAQ:BNTX

Intrinsic Alpha fair value

Locked

Current Price

$83.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.